Key facts
- Axoltis Pharma’s last known valuation is $3.8M (Jun 2016).
- It has raised $25.5M; the latest was Later Stage VC ($20.8M) in Dec 2025.
- Notable investors include ODDO BHF Group, Angelor, Auvergne Business Angels, Auvergne-Rhône-Alpes Regional Future Industry Fund, Cenitz — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Axoltis Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Axoltis Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axoltis Pharma
Operator of a biotechnology company intended to treat patients suffering from severe neurological disorders. The company's drugs assist neural repair in treating patients with traumatic degenerative disorders of the central nervous system, faced with high unmet medical needs, enabling patients to get treatment for neurodegenerative diseases and improve functional recovery and quality of life.
- Sector
- Healthcare
- HQ
- Clermont-Ferrand, France
- Founded
- 2003
- Employees
- 15
- Website
- axoltis.com/
- Ownership
- Privately Held (backing)
Axoltis Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axoltis Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axoltis Pharma in its N-PORT filings yet. We sweep new filings monthly.